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Multimodality Somatostatin Analog for Fluorescence-Guided Surgery in Cancer 
Abstract 
Servando Hernandez Vargas, B.S. 
 
Advisory Professor: Ali Azhdarinia, Ph.D. 
 
Cancer surgery remains the primary curative treatment for most solid cancers and has major 
therapeutic implications for patients with neuroendocrine tumors (NETs). Anatomical and 
functional imaging technologies are widely used during the pre- and postoperative stages, but 
intraoperative disease recognition relies on direct visual inspection and the hands of surgeons. 
The limited number of clinical tools for real-time intraoperative visual feedback restricts the ability 
to remove the complete cancer source and is partially responsible for the high rate of disease 
recurrence in patients. Intraoperative imaging with fluorescent contrast agents has the potential 
to improve the ability of surgeons to detect tumors when compared to visual inspection and hands 
alone. Growing clinical evidence highlights the utility of fluorescence-guided surgery (FGS) in 
cancer. However, the translation of fluorescently labeled imaging agents has been limited by the 
semi-quantitative nature of the optical signal. Strategies to combine radioactive and fluorescent 
contrast have been developed to enable cross-validation of fluorescent agents with nuclear 
imaging and quantitative analysis. While several methods for dual labeling have been proposed, 
the selection of a clinical radiotracer as a model system provides a proven targeting approach. 
Since adding a fluorophore to a radiotracer could adversely affect its imaging properties, we 
developed a multimodality chelator (MMC) to synthesize a bioactive analog of the NET imaging 
agent, 68Ga-DOTA-TOC. The MMC serves as a “radioactive linker” to bridge the near-infrared 
fluorescent (NIRF) dye IR800 and targeting moiety Tyr-3-octreotide (TOC), producing 
MMC(IR800)-TOC. Here, we first examined the radiochemical and pharmacological properties 
of the dual-labeled analog. Subsequently, we evaluated the ability of the fluorescent somatostatin 
analog to selectively target tumors that overexpress the somatostatin receptor subtype-2 
(SSTR2) and demonstrate utility for FGS. We used 67Ga/68Ga for quantitative biodistribution 
 vi 
studies and cross-validated semi-quantitative findings from fluorescence-based detection 
methods. The observed receptor-mediated uptake in mice was confirmed via ex vivo analysis at 
the macro-, meso- and microscopic levels. These results showed the impact of dual labeling on 
tracer validation and the effectiveness of the MMC technology for developing a novel FGS agent. 
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CHAPTER 1: INTRODUCTION 
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The role of surgery in cancer 
The significant role of cancer surgery in patient care continues to evolve alongside 
breakthroughs in medical and molecular oncology (1). Beyond being an isolated and radical 
specialty, surgical oncology also extends to cancer prevention, diagnosis, staging, risk-reduction 
and multidisciplinary management. Historically, surgery has served as the first-line therapy for 
risk- and symptom-reduction for most solid cancers, and can be curative if complete resection is 
achieved (1–5). However, the presence of positive surgical margins (PSMs) occur when the 
surgical procedure does not remove the entire tumor and cancerous cells are left behind (6–10). 
As outlined by the International Union Against Cancer (UICC), the extent of residual cancerous 
tissue serves as a prognostic factor and may determine patient outcomes (11, 12). 
 Several surgical procedures are routinely employed for debulking or relieving symptoms. 
However, the ultimate goal of cancer surgery is to remove the complete source of the disease 
while sparing healthy tissue. Anatomical and molecular imaging technologies are available during 
pre- and postoperative stages for surgical planning and surveillance, respectively. Conversely, 
intraoperative disease recognition relies on direct visual inspection by the surgeon along “hands-
on” palpation and tactile-guidance (1). As a result, significant effort has been made to bridge 
preoperative imaging with real-time intraoperative imaging to address a critical unmet need in 
cancer surgery. 
 
Challenges, unmet needs and new technologies in surgical oncology 
 The advent of minimally invasive and robotic-assisted surgeries have revolutionized the 
surgical standard of care and improved patient outcomes (1, 4, 5). Despite the surge of 
technological advances in the operating room (OR), surgeons continue to rely on palpation and 
visual inspection for the discrimination between diseased and healthy tissue. Lesions that are 
undetectable to the naked eye, i.e., occult or too small, further complicate the ability of surgeons 
to differentiate cancerous from healthy tissue intraoperatively. In this context, the available gold 
standard for the semi-real-time intraoperative evaluation of PSMs is based on histopathology 
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(13, 14). However, frozen section analysis has inherent challenges that may require extensive 
sampling of the wound bed and adjacent areas. This labor- and time-intensive method can also 
lead to the unnecessary removal of physiological elements or the partial extraction of diseased 
tissue (13–15). Patients with residual cancer clusters left behind due to incomplete resections or 
inconspicuous micrometastases have been shown to have a high recurrence rate and worse 
prognosis (6).  
To improve upon existing methods for intraoperative tumor identification, live navigation 
using light-emitting agents that color code the surgical field of view has emerged as a promising 
alternative (16–18). Enhancing intraoperative disease mapping via optical imaging is projected 
to cause a paradigm shift in surgical oncology. The benefits of using fluorescence-guided surgery 
(FGS) would not only support current guidelines focused on preservation of anatomical structures 
(7, 8), but would also complement rapidly expanding minimally-invasive and robotic technologies 
where tactile-guidance is not possible (1, 7, 8). 
 
The nature of biomedical optics and its role in clinical oncology 
The foundation of in vivo optical imaging is based on the movement of photons through 
tissues and their interaction with tissue elements. Living organisms have endogenous contrast 
that originates from many biological substances, which dictate the extent of photon scattering 
(attenuation), absorption and emission (autofluorescence) characteristics of the living system 
(19, 20). These dynamic phenomena have been used to produce visual contrast, thus generating 
an opportunity for the application of biomedical optics (21). Alternatively, fluorescent signal can 
be produced through administration of exogenous contrast agents. These agents have clinical 
utility and are generally categorized based on whether the photons emitted are in the visible 
electromagnetic spectrum (400-600 nm) or in the near-infrared (NIR) region (700-900 nm) (22, 
23). 
The first clinical use of a fluorophore for enhancing the real-time localization of tumors 
dates back to 1948 when surgeons used fluorescein (ex/em = 494/512 nm) to aid in the 
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localization and identification of intracranial neoplasms (24). The authors concluded that 
fluorescein proved useful in confirming the presence or absence of neoplastic tissue. 
Additionally, the authors suggested the contrast-enhancing technique as a method for evaluating 
the state of infiltrating gliomas during surgery. Since then, the clinical benefits of fluorophores 
have supported the expansion of food and drug administration (FDA)-approved visible 
fluorescent agents (Table 1) for tumor detection and sentinel lymph node (SLN) mapping, as well 
as others (18). However, the wide-spread clinical translation of visible fluorophores has been 
restricted by their relatively low maximum resolution and penetration depth. These limitations are 
a result of the complex optical properties of the dyes, predominantly a combination of 
autofluorescence and photon attenuation that are particularly amplified in the 400-600 nm range 
(21) (Fig. 1).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Currently used Food and Drug Administration-approved fluorescence probes. Table 
as originally published with permission from Nagaya T, Nakamura YA, Choyke PL and Kobayashi 
H (2017) Fluorescence-Guided Surgery. Front. Oncol. 7:314. doi: 10.3389/fonc.2017.00314. 
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Figure 1. NIR fluorescence is more suitable for in vivo imaging applications than visible-light 
fluorescence. Near-infrared (NIR) fluorophores (700–900 nm) have deeper tissue penetration 
and lower background fluorescence than visible-light fluorescence, resulting in enhanced 
signal-to-noise ratios. The detection depths achievable with the currently available 
instrumentation ranges from millimeters with NIR fluorescence to micrometers with visible-
range fluorescence. Figure as originally published with permission from Ray R. Zhang, Alexandra 
B. Schroeder, Joseph J. Grudzinski, Eben L. Rosenthal, Jason M. Warram et al. (2017). Nat Rev 
Clin Oncol. doi: 10.1038/nrclinonc.2016.212. 
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Fluorophores in the NIR spectrum provide several advantages that make long-wave 
imaging specifically suitable for clinical use. This includes enhanced photon transport that leads 
to higher penetration depths. It also results in lower background signal due to reduced 
autofluorescence and photon scattering (Fig. 1) (25). The increasing demand for NIR dyes has 
been accompanied by the commercialization of FDA-approved NIR imaging devices (Table 2), 
which consist of an excitation light source, collection optics (filters), a NIR camera and a display 
unit (Fig. 2) (26, 27). Customization of the acquisition features of the imaging device can result 
in improved resolution and sensitivity with reduced amounts of dye (28). Thus, the concomitant 
development of a drug intended for use with a specific device (drug-device combination) can 
strongly support translational efforts.  
Thus far, the clinical adoption of NIRF imaging has been restricted to the high-dose 
administration (up to 25 mg) of the non-targeted dye, indocyanine green (ICG, ex/em = 785/830 
nm). ICG has been widely used for the assessment of blood flow and tissue perfusion, SLN 
mapping, and tumor margin delineation (29–31). Since ICG lacks functional groups for 
bioconjugation, there has been an increasing demand for new NIR beacons that can build upon 
its clinical success, while providing improved stability and optical properties (25, 32). 
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Figure 2. The mechanics of NIR fluorescence imaging. NIR fluorescent contrast agents are 
administered intravenously, topically or intraparenchymally. During surgery, the agent is 
visualized using an NIR fluorescence imaging system of the desired form factor (above the 
surgical field for open surgery, or encased within a fiberscope for minimally-invasive and 
robotic surgery). All systems must have adequate NIR excitation light, collection optics, 
filtration and a camera sensitive to NIR fluorescence emission light. An optimal imaging system 
includes simultaneous visible (white) light illumination of the surgical field, which can be 
merged with the generated NIR fluorescence images. The surgeon’s display can be one of 
several form factors, including a standard computer monitor, goggles or a wall projector. 
Current imaging systems operate at a sufficient working distance that enables the surgeon to 
operate and illuminates a sizable surgical field. Abbreviations: LED, light-emitting diode; NIR, 
near-infrared. Figure as originally published with permission from Alexander L. Vahrmeijer, 
Merlijn Hutteman, Joost R. van der Vorst, Cornelis J. H. van de Velde, John V. Frangioni. Nat. 
Rev. Clin. Oncol. 10, 507–518 (2013). doi: 10.1038/nrclinonc.2013.123. 
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Strategies for targeted FGS agent development 
Conjugating a fluorophore to a ligand that binds to a target overexpressed in cancer would 
generate a disease-specific probe. The targeted approach would, in turn, require reduced 
amounts of contrast agent (μg range), and potentially lower risks of toxicity and non-specific 
signal (33). In its simplest form, the anatomy of a receptor-specific agent is comprised of a dye 
attached to a targeting moiety via a standard chemical linker. Depending on the receptor of 
interest, the targeting ligand may be a small molecule, antibody, peptide or other type of 
molecule.  To facilitate the development of targeted probes, fluorophores have been synthesized 
to contain reactive groups for facile bioconjugation, i.e., via amine-reactive (i.e., NHS-ester) or 
sulfhydryl-reactive (i.e., maleimides) crosslinker chemistry, copper-free click chemistry (i.e., 
DBCO), etc. IR800 (ex/em = 774/789 nm) has emerged as a preferred bioconjugatable NIRF 
dye that positions as an excellent candidate for FDA-approval based on desirable optical 
properties, robust in vivo photostability and demonstrated safety both pre-clinically and clinically 
(17, 25, 34, 35). 
Seminal first-in-human studies have shown the feasibility of utilizing targeted agents for 
FGS in several cancers. Notably, these targeted optical agents have proven to significantly 
enhance the identification/delineation of tumor deposits and increase resection-rates of 
malignant tissue when compared to palpation and visual inspection alone. Van Dam et al. 
reported the first clinical study with a targeted fluorophore and showcased the potential for 
improved cytoreductive surgery (36). This successful first-in-human application used a folate 
analog conjugated to fluorescein isothiocyanate (folate-FITC, ex/em = 495/520 nm) for tumor-
specific intraoperative imaging of folate receptor-α (FR-α) overexpression. The subsequent rapid 
expansion of targeted imaging probes in the NIR region is exemplified by the development of 
OTL38, a folate analog conjugated to a NIRF dye (796 nm). OTL38 has been reported to enable 
higher detection rates of malignant tissue during surgery in FR-α positive malignancies including 
ovarian cancer (37), renal cell carcinoma (38), lung/pleural nodules (39) and others. Recently, 
IR800 has been conjugated to clinically used antibody therapeutics, such as bevacizumab (40) 
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and cetuximab (34), for successful receptor-mediated surgical navigation and tumor margin 
assessment in breast cancer and metastatic head and neck cancer patients, respectively. 
While the utility of FGS in cancer continues to be supported by growing clinical evidence, 
the pathway for the successful clinical translation of optical probes is vague (41–45). The 
laboratory-to-human translation of targeted imaging probes continues to be largely restricted by 
the complexity of biomedical optics, the lack of a clinical benchmark and validation difficulties 
posed by the semi-quantitative nature of the optical signal (17, 21). Efforts to address FDA 
requirements have more often than not been particularly hampered by the lack of robust and 
standardized validation methods. The general consensus is that in order for image-guided 
surgery with fluorescent contrast agents to go from bench-to-bedside, it is fundamental to set 
standards with defined metrics for reporting and quantification in FGS (46–48). These realities 
have spurred increased interaction between surgeons, scientists and regulatory agencies to 
critically assess the value of implementing the optical technology in the OR and to identify optimal 
routes for its safe and efficacious translation (41–45).   
 
Dual labeling as a validation strategy 
 It has been estimated that ~10% of the successful dye excitation events typically emit 
radiation (49). The intrinsic low energy radiated photons are then highly scattered in tissue, 
leading to signal loss and restricted depth of penetration, which significantly limits the acquisition 
efficiency by the optical imaging device. This scattering phenomenon largely contributes to the 
ambiguity associated with precisely measuring the fluorescent signal being produced (46–48). 
To overcome these quantitative limitations, efforts towards the combination of NIRF (>750 nm) 
and nuclear contrast into single, molecularly targeted agents have emerged (50–55). The 
synergistic potential of the optical and nuclear modalities has been recognized as a promising 
platform that allows the quantitative assessment of fluorescence-based imaging. The 
complementary nature arises from the shared and overlapping characteristics, namely the use 
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of labeled probes, photon processing, comparable detection sensitivities (high picomolar-
femtomolar range), and the need to extract quantitative data. (43). 
Dual labeling provides a framework that leverages the key strengths of each technique 
and overcomes the individual drawbacks from fluorescence-based and radionuclide-based 
monolabeled probes. More precisely, the development of such dynamic platforms allows the 
integration of signal reporters that synergistically provide higher spatiotemporal resolution and 
higher penetration depth, by means of low energy (1-2 eV) and high-energy photons (~80-511 
keV), respectively. Dual labeling also provides intrinsic validation through correlation of co-
localized NIRF/radionuclide signals in tissues. Moreover, dual labeling serves as a method to 
quantitatively assess pre-clinical NIRF imaging using standard nuclear imaging descriptors such 
as % injected dose per gram of tissue (%ID/g) (50–55). Importantly, dual labeling has the 
potential to extend preoperative surgical planning into the OR for real-time intraoperative cancer 
detection. 
Given the ambitious nature of the dual labeling strategy, several design challenges need 
to be addressed. Depending on the structural scheme, the final multimodal reporter typically 
consists of a ligand, a linker, a chelator and the fluorescent dye – components which taken all 
together may be as large as the targeting moiety itself (50, 51, 55). In designing a NIRF/nuclear 
probe, maximum retention of optical characteristics, radiochemical properties, receptor affinity 
and biodistribution is desirable. Thus, careful consideration of the type/position of labels and the 
size relation is critical. Indeed, the literature is replete with instances where the chelator-isotope 
combination, radiochemical formulation or increase in molecular weight, significantly influenced 
the dye stability (56), coordination chemistry (57)  or pharmacodynamic/pharmacokinetic 
properties (58–60), respectively, via alterations in the charge distribution and hydrophobicity 
characteristics.  
Heptamethine cyanine dyes are the most commonly used fluorophores for dual labeling 
based on their longer-wavelength fluorescence, high quantum yield, high photostability and a 
range of bioconjugatable derivatives (61, 62). This class of NIR dyes consists of aromatic 
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heterocycles bridged by polymethine chains, which may be functionalized with cyclohexenyl 
substitutions to improve their photophysical properties. Additionally, sulfonic acid groups have 
been added to certain dyes to increase hydrophilicity. Nonetheless, the inherent lipophilic nature 
of fluorescent molecules, coupled with their generally uneven charge distribution, pose 
challenges in maintaining the rapid clearance properties of peptides. Specifically, IR800 has a 
hydrophobic core with a highly anionic surface charge and has been reported to primarily clear 
through the liver (63, 64). Previously, it has been shown that upon IR800 conjugation, a cyclic 
Arg-Gly-Asp (RGD) analog had a -4 net charge with an unbalanced charge-to-hydrophobicity 
distribution. Although the tumor targeting capabilities were not affected by such physicochemical 
properties, the IR800 conjugated RGD analog showed higher nonspecific accumulation in the 
liver and abdominal/thoracic walls when compared to a fluorescent RGD analog with 0 net charge 
and a well-balanced charge distribution (64).  
Proof-of-concept studies have shown that dual labeling can be practical in the pre-clinical 
setting for the characterization of promising candidates for targeted FGS. For instance, the RGD 
peptide has been functionalized with the ICG analog, cypate, and 111In-DOTA for angiogenesis 
evaluation via αvβ3 integrin overexpression (65). The multimodal RGD derivative was found to 
retain in vitro receptor affinity and to target tumors in vivo as determined by consistent radioactive 
and fluorescence intensity data, indicating labeling did not interfere with binding properties. In 
another study, Zhang et al. developed the first bimodal positron emission tomography 
(PET)/fluorescent probe for gastrin-releasing peptide receptor targeting and assessed receptor-
binding affinity upon dye conjugation (66). Using PET/CT and fluorescence imaging along cross-
validation via biodistribution studies, the authors showed receptor-mediated uptake and high 
multimodal image contrast with potential for clinical translation. Similarly, Baranski et al. reported 
the synthesis and evaluation of a library of dual labeled agents derived from the radiotracer 68Ga-
PSMA-11 for prostate-specific membrane antigen targeting (67). The authors found that the 
development of fluorescent-PSMA-11 analogs is feasible and concluded that these multimodal 
agents are promising candidates for pre-, intra- and postoperative imaging of prostate cancer. 
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Selection of neuroendocrine tumors as a disease model for FGS 
The selection of a clinically established ligand-receptor complex as a model system would 
logically support the characterization of an FGS agent. This rationale is especially applicable to 
the somatostatin ligand-receptor system, a hallmark in neuroendocrine tumors (NETs). NETs are 
a heterogeneous family of slow-growing, poorly understood neoplasms with a mostly sporadic 
etiology and small familial risk (68) that would greatly benefit from the advantages provided by 
FGS given their propensity to form micrometastases (69–71). Although NETs are classified as 
relatively uncommon tumors, the 20-year limited-duration prevalence rate for the US population 
was estimated to have a 1.7-fold increase from 2004 (103,312) to 2014 (171,321) (72). They also 
have an annual overall incidence rate (6.3%) rising more rapidly than other more widespread 
cancers (i.e., lung and breast cancer) (73, 74). Because of the extended distribution of 
neuroendocrine cells across the body, NETs have a large spatial incidence encompassing the 
foregut, midgut and hindgut, with primary tumor sites occurring commonly in the lungs and 
gastrointestinal tract (68, 75). NETs are generally categorized as well-differentiated (low to 
intermediate grade) or poorly-differentiated (aggressive, high grade) based on factors such as 
histopathology, proliferation rate and functional status. Functioning tumors lead to additional 
debilitating symptoms due to excess peptide and hormone secretion and are routinely treated 
with somatostatin analogs (SSAs), the only proven therapy for hormonal hypersecretion in NETs 
(76).  
The somatostatin receptor (SSTR) is a distinctive feature of NET biology and is 
overexpressed in 75-95% of the cases. Although the SSTR family is composed of 5 types of G-
protein coupled transmembrane receptors, the SSTR type 2 (SSTR2) is the most abundant 
subtype and has proven to be a fundamental target for diagnostic imaging and treatment with 
SSAs (77). Two mechanisms of SSTR2 signaling and regulation are key for the clinical 
effectiveness of SSAs. First, SSTR2 coupling to adenylyl cyclase (AC) via pertussis-toxin 
sensitive Gi/o proteins inhibits AC, closes voltage-sensitive calcium channels and opens specific 
potassium channels (78). This in turn causes a reduction in two critical second messengers, 
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cyclic adenosine monophosphate (cAMP) and cytosolic calcium, which results in a synergistic 
inhibitory effect on hormonal hypersecretion (77). Second, rapid receptor phosphorylation leads 
to the desensitization and internalization of the ligand-receptor complex via clathrin-coated pits 
(78) that allows the intracellular accumulation of SSAs. Given the current clinical use of SSAs 
that have been iteratively optimized over the last 30 years, NETs are an ideal disease model for 
the development of an SSA-based FGS agent. 
 
Evolution of SSAs and therapeutic management of NETs 
The bioengineering of the first generation FDA-approved, eight amino acid SSAs 
octreotide (peptide sequence, -D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)) and lanreotide 
(peptide sequence, --D-NaI-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2) has served as the basis for 
the treatment of functioning NETs (77). The therapeutic benefits of these SSAs are a result of 
their ability to inhibit the secretion by and growth of SSTR2-overexpressing tumors. Octreotide 
was first synthesized in 1982 (79) and entered clinical trials in 1984 (80). The synthesis of 
lanreotide was first reported in 1987 (81) with clinical studies beginning in 1989 (82). Both SSAs 
are synthetic agonists that have high SSTR2 affinity, lower SSTR3/SSTR5 affinity and no 
SSTR1/SSTR4 affinity (77). Importantly, these SSAs activate SSTR2 at similar nanomolar 
concentrations compared to the native counterparts, somatostatin-14 and somatostatin-28 (83). 
Because of their highly improved in vivo stability, octreotide and lanreotide have been further 
functionalized with radioactive elements and structural complexes capable of trapping isotopes 
for nuclear imaging. Octreotide was the first SSA to obtain clinical importance (84), which led to 
the development of a radiolabeled analog, iodine-123 labeled Tyr-3-octreotide (TOC), in 1989 
for localizing tumors with a gamma camera (85). This initial success was followed by FDA-
approval of 111In-labeled DTPA-D-Phe1-octreotide (OctreoScan) in 1994 (86), the first 
radiopharmaceutical that was routinely used in the clinic for planar/SPECT imaging and radio-
guided surgery. The subsequent introduction of the metal chelator, DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) (87, 88), remarkably improved the stability of 
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radioconjugates and permitted the implementation of PET isotopes (i.e., 68Ga, 64Cu) for NET 
imaging and theranostic isotopes (i.e., 90Y, 177Lu) for peptide receptor radionuclide therapy 
(PRRT). 
Advances in the management of NETs have translated into earlier, more precise 
diagnoses with 68Ga-DOTA-TOC and 68Ga-DOTA-TATE (structural analog with acidic C-
terminus) as the PET imaging gold standards. Additionally, improved therapeutic options have 
emerged, including PRRT (89) and the approval of new targeted drugs (90). Despite these 
advances, surgery remains the only potential curative treatment for NETs. Importantly, surgery 
for NETs is indicated not only in localized cases, but also in advanced stages of the disease for 
debulking and palliating the abnormal tissue/hormonal burden. Given the relatively indolent and 
slow-growing nature of NETs, diagnosis is often delayed for many years, and at the time of 
presentation, 40-70% of patients have nodal or liver metastases (76). Although surgery extends 
the overall survival even in cases presenting metastatic disease, patients with NETs have a 5-
year recurrence rate of more than 90%. This recurrence is primarily attributed to residual disease 
and incomplete removal of the cancerous metastatic lesions (69–71, 76, 91). Gamma probe-
guided ultrasound (92) and radio-guided surgery (93) have been implemented in the OR to 
improve the detection of deep-seated and visually-challenging NET deposits. The added 
advantage of radio-guided surgical navigation via audible signal is that the SSTR2-targeting 
radiopharmaceutical used intraoperatively can also be used pre- and postoperatively for surgical 
planning and postoperative surveillance imaging. However, the inability to obtain visual 
information on tumor location significantly limits this approach. Consequently, fluorescent SSAs 
are candidates that can address the limitations of radio-guided surgery.   
 
The multimodality chelator (MMC) as a novel strategy for validating an FGS agent 
Numerous examples of targeted optical probes in pre-clinical stages for NET diagnosis 
and image-guided surgery are found in the literature (94). For instance, octreotide, octreotate, 
TOC and TATE (Tyr-3-octreotate) have been coupled to a range of visible and NIR dyes including 
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fluorescein (95), rhodamine derivatives (96) and cyanine dye derivatives (97–99). However, 
validated FGS agents for SSTR2 targeting are lacking.  
 To support the validation and translation of FGS agents, we propose the application of a 
novel, radioactive linker known as a multimodality chelator (MMC) that maximizes the distance 
between the pharmacophore and the fluorescent label (100). The implementation of the MMC 
permits “true” quantification and cross-validation through NIRF/nuclear signal co-localization. We 
apply a translational focus to our dual labeling strategy with the MMC by developing a fluorescent 
analog of the PET imaging gold standard in NETs, 68Ga-DOTA-TOC. Thus, we hypothesize that 
SSTR2 targeting with 68Ga-DOTA-TOC would serve as a proven model for a dual-labeled 
SSA for FGS.  To test this hypothesis, DOTA was substituted with the MMC, which minimized 
the steric effects of dye labeling, while allowing the retention of the chelator-peptide footprint of 
DOTA-TOC. The role of the MMC was subsequently redefined to serve as a radioactive linker 
that maximizes the distance between the pharmacophore (TOC) and the NIRF label (IR800). The 
arrangement of MMC(IR800)-TOC (Fig. 3) is possible because of the versatility afforded by the 
macrocyclic compound DO2A (1,4,7,10- tetraazacyclododecane-1,7-bis(t-butyl acetate)), which 
structurally mimics DOTA, but permits selective functionalization of the chelator. Upon synthesis 
of an MMC with acetate and azide-containing pendant arms, Tyr3-octreotide (TOC) conjugation 
was first performed using solid-phase peptide synthesis, and the resulting intermediate was then 
fluorescently labeled with IR800 via copper-free click chemistry in solution, respectively. 
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Figure 3. Structure and components of the SSTR2-targeted intraoperative imaging agent. 
MMC-mediated dual labeling enables quantitative characterization of the fluorescent 
somatostatin analog, MMC(IR800)-TOC. 
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Previous efforts to develop somatostatin analogs for nuclear/NIRF imaging have been 
attempted and major limitations were identified. For instance, Santini et al. successfully 
synthesized the fluorescent/radiolabeled hybrid Cy5-111In-DTPA-Tyr3-octreotate (101); however, 
upon dye conjugation, loss of binding properties was observed. In vitro uptake studies showed a 
27.6-fold decrease in receptor binding compared to the monolabeled tracer 111In-DTPA-Tyr3-
octreotate (33.76%±1.22% applied dose vs. 1.32%±0.02%). In another study, Edwards et al. 
developed the multimodal SSA, cypate-labeled 64Cu/177Lu-DTPA-Y3-TATE (102). Results 
showed that despite having high in vitro binding affinity, the multimodal agent failed to internalize. 
This indicates that the addition of cypate altered the mechanism of action of the somatostatin 
agonist Y3-TATE. It was also reported that the high in vitro affinity did not translate to in vivo 
tumor binding (≤1% ID/g). Additionally, the probe had predominant hepatobiliary clearance 
(>90% ID/g of liver) and low kidney clearance, which is the inverse of traditional peptide-based 
radiotracers. The authors attributed the low in vivo accumulation to the loss of internalization 
rate, a hallmark of successful SSTR2-agonist imaging agents.  
Our approach to dual labeling yielded the first bioactive fluorescent analog of a clinical 
PET radiotracer (100), a strategy that further supports validation and translational efforts by 
integrating components that can address current scientific concerns and regulatory hurdles. 
Using 68Ga-DOTA-TOC provides a foundation that aligns with current clinical practices in NET 
management and a benchmark to guide optimization strategies. The use of the MMC technology 
potentially extends the pre- and postoperative PET utility of 68Ga-DOTA-TOC into the surgical 
suite, while generating a method to quantitatively validate the resulting intraoperative imaging 
agent. Importantly, 68Ga-DOTA-TOC would serve as an accompanying diagnostic for identifying 
candidates that would benefit from FGS with Ga-MMC(IR800)-TOC. In this project, we assess 
the performance and potential clinical utility of Ga-MMC(IR800)-TOC with the following specific 
aims: 
 
Aim 1. To determine the optimal radiosynthesis for 68Ga-MMC(IR800)-TOC: using clinically 
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relevant radiochemistry formulations (NaCl/acetone/fractionation), conditions will be optimized 
based on high labeling efficiency and maximum retention of fluorescence intensity after labeling. 
a) To quantify the radiochemical yield: radio-HPLC will be used to determine crude 68Ga 
complexation. 
b) To assess the optical integrity: a fluorescence reader will be used to assess dye intensity after 
radiosynthesis and normalized to unprocessed controls. 
 
Aim 2. To characterize the binding properties of 68Ga-MMC(IR800)-TOC in vitro: quantitation 
of receptor binding properties with radioligand assays will allow observation of SSTR2-cellular 
uptake and specificity. 
a) To quantify SSTR2-binding: cellular uptake will be examined using HCT116 cells that stably 
overexpress SSTR2 (HCT116-SSTR2) and compared to 68Ga-DOTA-TOC. 
b) To determine the specificity for SSTR2-binding: blocking studies will be performed with 
increasing amounts of the SSTR2-competitor, octreotide. 
 
Aim 3. To assess the imaging properties of 68/natGa-MMC(IR800)-TOC in xenografts: using 
an animal model with subcutaneous HCT116-SSTR2 tumors, the ability of the agent to provide 
tumor contrast will be assessed in vivo and validated ex vivo. 
a) To identify differences in the pharmacokinetics of 68Ga-MMC(IR800)-TOC and 68Ga-DOTA-
TOC: effects of dye labeling on the radiotracer will be determined by tissue biodistribution studies. 
b) To determine specificity for localizing SSTR2-overexpressing xenografts: using PET/CT and 
NIRF imaging, in vivo specificity (competition, non-targeted, control cell line) for cancer tissue 
will be assessed and validated. 
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General methods 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. Reversed-
phase high-performance liquid chromatography (HPLC) was performed on an analytical Hitachi 
LaChrom system using a Kinetex C18 column (2.6 μm) (Phenomenex) with a mobile phase of A 
= 0.1% TFA in H2O, B = 0.1% TFA in CH3CN (gradient: 0 min, 10% B; 12 min, 90% B); flow rate, 
1 mL/min. Radiochemical purities of ≥95% were assessed by radio-HPLC using an in-line 
radioactive detector (Berthold Technologies). 1H NMR and 13C NMR spectra were recorded at 
ambient temperature using 600 MHz IBM-Bruker Avance NMR spectrometers. Chemical shifts 
(δ) were reported (in ppm) downfield of tetramethylsilane.  
 
Labeling of MMC(IR800)-TOC with 68Ga, 67Ga, and Ga 
68Ga radiolabeling was performed using the acetone, NaCl and fractionation methods. 
For the acetone method, radiolabeling was performed as previously described (100). Briefly, 68Ga 
was eluted from a 68Ge/68Ga-generator with 5 mL of 0.1 M HCl and adsorbed onto a Strata-X 
cation exchange cartridge (Phenomenex). After purging residual HCl from the cartridge, 68Ga 
was collected with 98% acetone/0.02 M HCl (v/v) and 1 mCi was added to 20 nmol of 
MMC(IR800)-TOC (MW: 2835.1 g/mol) in 0.2 M sodium acetate (pH 4). Samples were heated at 
95° C for 15 min. Following Sep-Pak Light C18 (Waters) purification, the product was diluted with 
PBS and analyzed by radio-HPLC. For the NaCl method, the radioactive solution was processed 
identically to the acetone method with the exception of using a Bond Elut cation exchange 
cartridge (Agilent), a 5 M NaCl/5.5 M HCl solution as an eluent and 2 M sodium acetate (pH 4) 
as the reaction buffer. For the fractionation method, 68Ga was eluted from the generator with 5 
mL of 0.1 M HCl and collected separately as five 1 mL fractions. Only the fraction with the highest 
radioactivity was selected for radiolabeling. 100 μL of peak fraction containing 0.3-0.4 mCi of 
68Ga was then directly added to 20 nmol of MMC(IR800)-TOC in 2 M sodium acetate (pH 4). 
Finally, incubation, purification and analysis were performed identically to the acetone/NaCl 
methods. 
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For 67Ga radiolabeling, 67Ga-citrate was purchased from a radiopharmacy (Cardinal 
Health) and was added to an equal volume of 0.1 M HCl to produce 67GaCl3. The radioactive 
solution was then processed identically to 68Ga using the acetone method, with the exception of 
using 0.5 M ammonium acetate (pH 4.5) as the reaction buffer. Cold Ga labeling was performed 
with non-radioactive gallium according to methods established above for the radiolabeled 
compounds. 60 nmol was mixed with a 4-fold molar excess of GaCl3 and heated at 95°C for 15 
min. The crude mixture was purified by ultrafiltration and the final product was characterized by 
HPLC. Ga-MMC(IR800)- TOC: MS, ESI+: m/z calculated for C135H170N22O34S2Ga, 2905.01; 
found m/z, 969.1 (M+3H)
3+
. 
 
Optical characterization upon radiolabeling 
 MMC(IR800)-TOC was radiolabeled with 68Ga using the fractionation, acetone and NaCl 
methods as previously described with the exception of using 1 nmol for the reaction. Briefly, 
incubation was performed for 15 min at 95ºC in eppendorf vials. Reaction mixtures were purified, 
collected in 1:1 saline ethanol solution and allowed to cool down for 30 minutes at room 
temperature. Samples were then transferred to black 96-well half-area plates with clear bottom 
(Greiner Bio-One). Fluorescence intensity was measured using an Odyssey plate reader (LI-
COR) and normalized to unprocessed MMC(IR800)-TOC in 1:1 saline ethanol solution. For the 
mock, nonradioactive solutions, MMC(IR800)-TOC was processed identically to the radioactive 
solutions with the exception of not adding 68Ga. Each experiment was performed in triplicate. 
  
 Cell culture and animal models 
Athymic female nu/nu mice (Charles River Laboratories) were housed under standards 
of the Institutional Animal Care and Use Committee (IACUC) of the University of Texas Health 
Science Center at Houston and maintained on normal rodent chow. HCT116-SSTR2 cells were 
kindly provided by Dr. Carolyn J. Anderson (University of Pittsburgh, Pittsburgh, PA, USA). 
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HCT116 cells (CCL-247) were purchased from ATCC. HCT116-SSTR2 and HCT116-WT cell 
lines were cultured in RPMI 1640 medium with 10% (v/v) fetal bovine serum (FBS) and 
maintained at 37°C with 95% humidity and 5% CO2 atmosphere. HCT116-SSTR2 cells were 
additionally supplemented with 100 µg/ml Zeocin (Gibco). For all procedures, mice were 
anesthetized with 1-2% isoflurane. For xenografting, 6-8 weeks old mice were subcutaneously 
injected with 1×106 HCT116-SSTR2 or HCT116-WT cells in matrigel (Corning):PBS (1:1) in the 
shoulder. Studies were conducted 3-4 weeks post implantation when tumor size reached 
approximately 5-10 mm maximum diameter. 
 
Measurement of intracellular cAMP with the GloSensor assay  
HEK293-HA3-rsstr2-Glo cells, expressing both the GloSensor 22F cAMP plasmid 
(Promega) and HA-tagged SSTR2 (from Dr. A. Schonbrunn Lab, The University of Texas Health 
Science Center at Houston), were seeded at 100,000 cells/well in 96 well plates. After 24 h, the 
medium was aspirated and replaced with 90 μL of warm (28°C) equilibration medium (DMEM + 
10% FBS + 10 mM HEPES + 2% D-Luciferin). Plates were pre-incubated in a dark humidified 
chamber at 28°C for 2 h and then placed in a PolarStar Optima multiplate reader (BMG Labtech). 
Basal bioluminescence was measured and then 10 μl of NKH477 (final concentration = 10 μM) 
was added either with or without the appropriate SSA concentration. Readings were taken every 
2.5 min for 1 h. Data shown were obtained 20 min after agonist addition and are expressed as a 
percentage of the luminescence measured in the presence of NKH477 alone. Reprinted 
(adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa 
Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 10.1021/acsmedchem- 
lett.7b00125. These experiments were performed by Dr. Melissa Rodriguez and Dr. Agnes 
Schonbrunn in the Department of Integrative Biology and Pharmacology, McGovern Medical 
School, The University of Texas Health Science Center at Houston (100). 
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Measurement of receptor internalization  
Changes in cell surface expression of SSTR2 were measured in HEK293-HA3-rsstr2 
cells (from Dr. A. Schonbrunn Lab, The University of Texas Health Science Center at Houston) 
using ELISA, as previously described (78). Briefly, HEK293-HA3-rsstr2 cells were incubated with 
labeled peptides for 30 min at 37°C. After washing, cells were fixed, blocked with 1% BSA for 30 
min, and incubated overnight at 4°C with mouse anti-HA antibody (1:10,000). Cells were then 
washed with PBS and incubated at r.t. for 1 h with goat anti-mouse HRP-labeled secondary 
antibody (1:10,000). Cell surface receptor level was determined by incubating for 45-60 min with 
ABTS and then measuring optical density at 405 nm. Reprinted (adapted) with permission from 
Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa Rodriguez, et al. Copyright (2017) 
American Chemical Society. doi: 10.1021/acsmedchem- lett.7b00125. These experiments were 
performed by Dr. Melissa Rodriguez and Dr. Agnes Schonbrunn in the Department of Integrative 
Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science 
Center at Houston (100). 
Radioactive uptake studies  
HCT116-SSTR2 cells were seeded in 96-well plates (200,000 cells/well) and incubated 
with a 10 nM solution of 68Ga-MMC(IR800)-TOC or 68Ga-DOTA-TOC at 37oC for 1 h. For 
blocking, a 10 and 100-fold excess of octreotide was added prior to addition of the radiotracers 
to determine receptor specificity. At the end of the incubation period, cells were pelleted, media 
was removed, and cells were washed three times with PBS. The cells were then collected and 
radioactivity was quantified in a Wizard2 automated γ counter (Perkin Elmer) to determine uptake 
as percent of total radioactivity added. The procedure was repeated using non-SSTR2 
expressing HCT116-WT cells. Non-targeted 68Ga-MMC(IR800) was also tested in both cell lines 
to further demonstrate specificity. Each experiment was performed in triplicate. Reprinted 
(adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, Melissa 
Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 10.1021/acsmedchem- 
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lett.7b00125.  
Biodistribution in healthy mice  
Normal 4-6 week old female, athymic, nude mice were injected intravenously with 740 
kBq (20 μCi) of 68Ga-MMC(IR800)-TOC or 68Ga-DOTA-TOC. Under anesthesia, the mice were 
euthanized by cervical dislocation at 15 min, 1, and 3 h post-injection. Selected tissues were 
excised, weighed, and counted for radioactivity using the γ counter. The results were expressed 
as percentage of the injected dose per gram of tissue (%ID/g) and represent the mean±SD of n 
= 3 mice/time point. The total injected activity per mouse was determined from a known aliquot 
of the injected solutions.  
 
In vivo PET/CT imaging 
Mice (n=3) were intravenously injected with 5.55 MBq (150 μCi, 4 nmol) of 68Ga-
MMC(IR800)-TOC and non-invasive imaging was performed at 1 and 3 h after injection on a 
Siemens Inveon small-animal PET/CT scanner as previously described (57). Region-of-interest 
analysis was performed with the vendor software package (Inveon Research Workplace) to 
obtain tumor-to-background (TBR) ratios. 
 
In vivo NIRF imaging 
Mice (n = 5) were intravenously injected with Ga-MMC(IR800)-TOC (2 nmol, 5.67 µg) and 
imaging was performed at 3 and 24 h post-injection. In vivo NIRF images were acquired for 200 
ms without background subtraction using a custom-built electron-multiplying charge-coupled 
device (EMCCD) fluorescence imaging system at ex/em = 785/830 (103), and image analysis 
was performed with the ImageJ software package (NIH). At the conclusion of the imaging studies, 
the mice were euthanized and selected organs were excised and underwent ex vivo NIRF 
imaging using an IVIS Lumina II (Perkin Elmer). For the selection of a radiolabeling method for 
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in vivo applications, mice (n = 4 per group) were imaged at 24 h post-injection as previously 
described with the exception of administering 68Ga-MMC(IR800)-TOC (0.5 nmol, 1.42 µg). 
 
Biodistribution and ex vivo imaging 
Mice with HCT116-SSTR2 tumors were intravenously injected with 370 kBq (10 µCi, 2 
nmol) of 68Ga-MMC(IR800)-TOC or 67Ga-MMC(IR800)-TOC, and euthanized by cervical 
dislocation under anesthesia at 3 h and 24 h post-injection, respectively. Selected tissues were 
excised and underwent ex vivo optical imaging using an IVIS Lumina II with the following settings: 
lamp level (high), excitation (745 nm), emission (ICG), epi-illumination; binning (S); FOV (C, 10); 
f-stop (2); acquisition time (1 s). Region of interest analysis was performed with the vendor 
software package (Living Image) to measure fluorescence signals and obtain tumor-to-tissue 
ratios. Parameters were the same for all acquired images. At the completion of the optical 
imaging studies, tissues were weighed and counted for radioactivity using a Wizard2 automated 
γ counter. The total injected activity per mouse was determined from an aliquot of the injected 
solutions. The results were expressed as %ID/g and represent the mean±SD of n = 5 mice/time 
point. To examine specificity, uptake in SSTR2 negative HCT116-WT xenografts was examined 
by in vivo and ex vivo optical imaging 24 h after injection of Ga-MMC(IR800)-TOC (2 nmol). 
Tumors and key organs (muscle, pancreas, small intestine) underwent cryoconservation by 
embedding in OCT and freezing on dry ice for subsequent mesoscopic and microscopic analysis. 
The non-targeted Ga-MMC(IR800) analog was evaluated identically to the targeted agent. 
 
Mesoscopic and subcellular localization of Ga-MMC(IR800)-TOC in tissue sections 
Frozen sections (10 µm) of muscle, pancreas, small intestine and tumors (HCT116-
SSTR2 and HCT116-WT) from animals that were injected with Ga-MMC(IR800)-TOC (2 nmol) 
24 h prior to necropsy were used to localize the IR800 signal within the tissue. Using an Odyssey 
slide scanner (LI-COR), the sections were scanned and the fluorescence intensities in the 800 
nm channel were quantified on 16-bit images using ImageJ. ROIs were drawn around the outline 
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of each organ and means±SD were calculated using GraphPad Prism (n=3 mice/group). 
Adjacent sections underwent hematoxylin and eosin (H&E) staining to permit morphological 
analysis of the tissue. 
To analyze Ga-MMC(IR800)-TOC distribution and receptor specificity at the cellular level, 
frozen sections of HCT116-SSTR2 and HCT116-WT tumors (24 h post 2 nmol Ga-MMC(IR800)-
TOC injection) were fixed in 4% cold paraformaldehyde for 10 min and embedded in Mowiol 
mounting medium. For counterstaining, we added NucSpot Live 488 nuclear stain (Biotium) to 
the mounting medium (1:1000 dilution directly in Mowiol). Microscopic images were acquired on 
a confocal microscope (SP8, Leica), equipped with a 730 nm laser for IR800 detection and a 488 
nm laser for NucSpot Live detection, in combination with appropriate filters. These experiments 
were performed by Dr. Susanne Kossatz and Dr. Thomas Reiner in the Department of Radiology, 
Memorial Sloan Kettering Cancer Center, New York. 
 
Immunohistochemical staining of SSTR2 
To detect SSTR2 expression, immunohistochemistry (IHC) was carried out on frozen 
sections of xenograft tumor tissue (HCT116-SSTR2, HCT116-WT) using the Discovery XT 
processor (Ventana Medical Systems, Tucson, AZ) at the Molecular Cytology Core Facility of 
Memorial Sloan Kettering Cancer Center. After thawing, sections were baked at 50ºC for 1 h, 
followed by a 30 min incubation with Background Buster solution (Innovex, Richmond, CA). 
Sections were then incubated with the anti-SSTR2 rabbit monoclonal antibody (Abcam) at 2.2 
µg/ml for 5 h, followed by a 1 h incubation with biotinylated goat anti-rabbit IgG (Vector Labs). 
For detection, a DAB detection kit (Ventana Medical Systems) was used according to the 
manufacturer instructions. Sections were counterstained with H&E and cover-slipped with 
Permount (Fisher Scientific). Slides were digitalized using a MIRAX Slide Scanner 
(3DHISTECH). These experiments were performed by Dr. Susanne Kossatz and Dr. Thomas 
Reiner in the Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, with 
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the support of the Radiochemistry & Molecular Imaging Probes Core Facility and Molecular 
Cytology Core Facility at Memorial Sloan Kettering Cancer Center. 
 
Statistical analysis  
Graphs and calculations were performed with GraphPad Prism (v 5.01). All data are 
presented as mean±standard deviation (SD) as indicated. Group comparisons were performed 
with one-way ANOVA (with Bonferroni’s post-tests) or two-tailed t-tests. 
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MMC(IR800)-TOC efficiently chelates 68/67/natGa using clinically relevant formulations 
 DOTA provides high radiochemical yields alongside remarkable in vivo stability due to its 
kinetic inertness. Thus, by developing MMC(IR800)-TOC to structurally mimic the chelator-
peptide footprint from DOTA-TOC, we hypothesized that our multifunctional chelator retains high 
labeling efficiency using clinically applied formulations. 
  68Ga is a positron emitter (β+ = 89%, Eavg = 740 keV, Emax = 1899 keV) with desirable 
characteristics for peptide-based targeted imaging. With its 67.71 min half-life, 68Ga is compatible 
with the rapid pharmacokinetic profile of radiopeptides (104). Commercial 68Ge/68Ga generators 
are available for on-site production of 68Ga. Thus, 68Ga availability is not necessarily dependent 
on a cyclotron schedule, but on the parent radionuclide in the generator (68Ge t1/2 = 270.95 days) 
(105). By contrast, 67Ga is a gamma emitter (t1/2 = 3.26 days, Emax = 394 keV) that has been used 
in its salt form (i.e., 67Ga-citrate) as a radiopharmaceutical for assessing tumors, inflammation, 
infectious processes, etc., via scintigraphy and single-photon emission computed tomography 
(SPECT) imaging (106). However, 67Ga is produced by a cyclotron facility and distributed by 
radiopharmacies. 
 Our results show that 68Ga-MMC(IR800)-TOC production using the fractionation, acetone 
and NaCl formulations is achieved with high radiochemical yield (>80%) (Figs. 4a-c) and with 
>99% radiochemical purity following purification with a C-18 cartridge (Fig. 5). Figure 5 also 
shows the corresponding absorbance at 280 and 780 nm for purified 68Ga-MMC(IR800)-TOC. 
For 67Ga-MMC(IR800)-TOC radiosynthesis, a modified version of the Zhernosekov et al. 
formulation was developed in our laboratory as described in the methods section. The final 67Ga-
product was produced with high radiochemical yield (72.7±5.1%, uncorrected for decay) and 
>99% radiochemical purity following purification (Figs. 6a and 6b). The stability was examined 
by incubating 68Ga-MMC(IR800)-TOC in mouse serum at 37oC for 3 h and analyzed by radio-
HPLC (Fig. 7). No significant breakdown products or demetalation occurred following incubation. 
Finally, Ga-MMC(IR800)-TOC was produced using non-radioactive gallium and confirmed via 
mass spectrometry. These results indicate minimal impact of dye conjugation on the chelation 
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properties of the macrocycle. Moreover, they show that the MMC is a suitable DOTA substitute 
for Ga ions and can be used with multiple labeling methods. 
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Figure 4. Radiolabeling MMC(IR800)-TOC with clinically relevant 
68
Ga formulations. (a) 
Labeling conditions for each method. (b) HPLC chromatograms showing the radioactive trace 
of crude, non-decay corrected 
68
Ga-MMC(IR800)-TOC. (c) Radiochemical yields using 
fractionation, acetone and NaCl radiosynthetic methods. Data are presented as mean ± 
standard deviation (n=3).  
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Figure	5.	Purified	68Ga-MMC(IR800)-TOC.	HPLC	chromatograms	showing	absorbance	of	purified	68Ga-
MMC(IR800)-TOC	at	280	and	780	nm,	and	the	radioactive	trace.	
Figure 5. Purified 68Ga-MMC(IR800)-TOC. HPLC chromatograms showing absorbance of 
purified 68Ga-MMC(IR800)-TOC at 280 and 780 nm, and the radioactive trace. 
 
Reprinted (adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, 
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 
10.1021/acsmedchem- lett.7b00125.  
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Figure 6. 
67
Ga-MMC(IR800)-TOC. HPLC chromatograms showing the radioactive trace of (a) 
crude and (b) purified 
67
Ga-MMC(IR800)-TOC. 
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Figure 7. Stability of 
68
Ga-MMC(IR800)-TOC in mouse serum. HPLC chromatograms showing 
the radioactive trace of 
68
Ga-MMC(IR800)-TOC in serum up to 3 h.  
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Comparison of normalized fluorescence upon subjection to radiolabeling 
Given the differences in buffer concentrations and eluting solutions when utilizing the 
acetone, fractionation and NaCl methods for producing 68Ga-MMC(IR800)-TOC, we evaluated 
whether the selection of radiolabeling scheme resulted in differences in fluorescence intensity. 
 The normalized fluorescence intensity for each method is shown in Figure 8. For all 3 
methods, the mock, nonradioactive solutions retained >94% of the initial fluorescence in NaOAc 
buffers ranging from 0.2-2 M with eluting solutions specific for each scheme. Upon 68Ga addition, 
the acetone and fractionation methods showed similar fluorescence retention of 95.7±2.5% and 
94.6±2.1%, respectively. The NaCl scheme resulted in the normalized fluorescence decreasing 
to a final value of 85.1±2.3%, which was significantly different to the acetone and fractionation 
formulations (P < 0.05). This indicates that the addition of 68Ga to the NaCl reaction mixture is a 
contributing factor leading to a reduction in NIRF signal. Although we cannot draw definitive 
conclusions on the reasons leading to the significant decrease in fluorescence using the NaCl 
formulation, these results suggest that the selection of radiolabeling method may alter the 
spectral properties of 68Ga-MMC(IR800)-TOC.  
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Figure 8. Normalized fluorescence intensity of MMC(IR800)-TOC. Radioactive and 
nonradioactive (mock) solutions were prepared using three radiolabeling schemes 
(fractionation, acetone and NaCl) and normalized with unprocessed MMC(IR800)-TOC. *P < 
0.05. Data are presented as mean ± standard deviation (n=3).  
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Ga-MMC(IR800)-TOC retains intact pharmacological properties 
 The selection of the well-characterized SSTR2 agonist 68Ga-DOTA-TOC as a system for 
the development of a fluorescent counterpart provides an ideal benchmark to assess the 
pharmacological impact of conjugating IR800 via the MMC linker.  
Figures 9a and 9b show the potency of peptide conjugates for cAMP inhibition and 
receptor internalization in HEK293-SSTR2 expressing cells. Using Ga-DOTA-TOC as a 
reference standard, we found that Ga-MMC(IR800)-TOC is able to maximally inhibit NKH477-
stimulated cAMP formation with high efficacy in the sub-nanomolar range (0.066±0.012 nM). 
NKH477 is a water-soluble forskolin derivative that directly activates AC and catalyzes cAMP 
production (107). Also, Ga-MMC(IR800)-TOC effectively stimulates receptor internalization with 
an EC50 of 48.7±9.9 nM, which was comparable to the EC50 for Ga-DOTA-TOC (16.6±3.7 nM). 
These studies indicate that the MMC scaffold successfully minimizes the effects of dye 
conjugation and allows the retention of agonist properties despite the addition of a bulky dye. 
Thus, the MMC is an effective scaffold for production of a fluorescent DOTA-TOC analog with 
intact pharmacological properties. 
 
68Ga-MMC(IR800)-TOC binds specifically to SSTR2 and comparably to 68Ga-DOTA-TOC 
 To further assess cellular binding, uptake and blocking of the radiolabeled hybrid SSA 
was investigated according to published protocols (58). Results showed that 68Ga-MMC(IR800)-
TOC uptake was 25.0±1.7% (% of total radioactivity added) in HCT116-SSTR2 cells at 1 h (Fig. 
9c). Uptake in parental, non-SSTR2 expressing, HCT116 cells was 1.9±0.9%. The findings were 
in agreement with 68Ga-DOTA-TOC uptake (21.5 ±3.7%, Fig. 9c), further suggesting that IR800 
conjugation did not impact SSTR2-mediated binding capabilities. To further evaluate whether the 
MMC-dye complex was contributing to any non-specific binding, a non-targeted MMC analog, 
68Ga-MMC(IR800), was incubated with both SSTR2-expressing and non-expressing HCT116 
cells. Figure 9c shows that at 1 h, there is negligible uptake of 68Ga-MMC(IR800) by either cell 
line. Blocking studies with increasing concentrations of octreotide yielded a dose-dependent 
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reduction of 68Ga-MMC(IR800)-TOC binding (Fig. 9d). The presence of a 10 and 100-fold 
octreotide excess resulted in a 78.5±9.6% and 93.7±1.6% reduction in 68Ga-MMC(IR800)-TOC 
binding, respectively. Taken together, these results support the data from the in vitro 
pharmacological assays and provide robust evidence that indicate receptor-mediated uptake of 
the dual-labeled agent.  
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Figure 9. In vitro characterization of 
68/nat
Ga-MMC(IR800)-TOC. Potency of peptide conjugates 
for (a) cAMP inhibition and (b) receptor internalization in HEK293-SSTR2 expressing cells. (c) 
Cellular uptake and (d) blocking of peptide conjugates in HCT116-SSTR2 and wild type HCT116 
cells. *P < 0.0001. Experiments for (a) and (b) performed by Dr. Melissa Rodriguez and Dr. Agnes 
Schonbrunn in the Department of Integrative Biology and Pharmacology, McGovern Medical 
School, The University of Texas Health Science Center at Houston. 
 
Reprinted (adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, 
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 
10.1021/acsmedchem- lett.7b00125.  
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68Ga-MMC(IR800)-TOC undergoes time-dependent elimination in vivo 
High biostability and hydrophilicity are desirable properties for a clinical imaging 
radiopeptide since they favor the renal-urinary mode of excretion over hepatobiliary excretion, 
thus enabling tumor visualization in the abdominal cavity (108, 109). 68Ga-DOTA-TOC has high 
in vivo kinetic inertness and hydrophilicity (log P = -2.9) (110), allowing it to rapidly clear from 
non-target tissues and provide a low noise floor to enhance tumor detection sensitivity.  
To evaluate the impact of dye conjugation on the pharmacokinetics, we performed 
radioactive biodistribution studies at 15 min, 1 h and 3 h post-injection and results are 
summarized in Figure 10 and Table 3. 68Ga-MMC(IR800)-TOC undergoes time-dependent 
elimination from circulation and healthy tissues up to 3 h post-injection. Kidneys were identified 
as the primary clearance route, which suggests that the fluorescent counterpart, despite the 
addition of multiple aromatic groups, retains the hydrophilic character of the parent radiopeptide. 
IR800 conjugation did increase clearance through the reticuloendothelial system (RES) (liver and 
spleen) and resulted in longer circulation in blood, however, the radioactive fractions in these 
tissues decreased progressively with time and may provide suitable tumor contrast in the 
abdomen region at a delayed time point (i.e., > 3 h). At other sites of interest, such as the lungs, 
high 68Ga-MMC(IR800)-TOC signal was persistent up to 3 h, while the 68Ga-DOTA-TOC signal 
was significantly higher at the pancreas up to 1 h (P < 0.05). The radioactive signal decreased 
over time for both agents in the remaining tissues.  
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Figure 10.  Radioactive biodistribution in healthy mice. Tissue uptake values for 
68
Ga-
MMC(IR800)-TOC and 
68
Ga-DOTA-TOC. 
Table 3.  Biodistribution results (%ID/g) for 
68
Ga-MMC(IR800)-TOC and 
68
Ga-DOTA-TOC. 
Reprinted (adapted) with permission from Sukhen C. Ghosh, Servando Hernandez Vargas, 
Melissa Rodriguez, et al. Copyright (2017) American Chemical Society. doi: 
10.1021/acsmedchem- lett.7b00125.  
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68Ga-MMC(IR800)-TOC binds to SSTR2 xenografts in vivo and is visualized using PET/CT 
 68Ga-DOTA-TOC combines rapid tumor accumulation (80% of the dose within 30 
minutes), low non-specific binding and rapid renal clearance, with suitable contrast being 
achieved 1 to 1.5 h after agent administration (86). To examine the tumor targeting properties of 
the dual-labeled agent, MMC(IR800)-TOC was radiolabeled with 68Ga and administered to mice 
bearing HCT116-SSTR2 xenografts for PET/CT imaging at 1 and 3 h post-injection. 
Accumulation at the tumor site can be seen at 1 and 3 h (Fig. 11a), with tumor-to-background 
ratios of 1.9±0.7 and 2.6±0.9 (Fig. 11b), respectively. PET/CT imaging was in agreement with 
the pharmacokinetic data obtained in healthy mice. The highest signal was observed in the 
kidneys, indicating renal clearance. Prominent lung and liver signal was also visualized at both 
time points, indicating involvement of the RES organs during clearance. These results provide 
evidence of in vivo SSTR2 targeting capabilities and suggest that delayed imaging (>> 3 h) may 
provide increased contrast in the thoracic and gastrointestinal regions. 
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Figure	11.	PET/CT	imaging	of	HCT116-SSTR2	xenografts	1	and	3	h	after	injection	of	68Ga-MMC(IR800)-
TOC.	(a)	Coronal	images	and	maximum-intensity	projections	(MIPs)	are	shown	(arrow	indicates	tumor).	(b)	
Ratio	of	the	signal	in	tumor	and	background	tissue.	Data	are	presented	as	mean	±	standard	deviation	
(n=3).		
b
a
MIP
Coronal
1 h 3 h
Figure 11. PET/C  imaging f HCT116-SSTR2 xenografts 1 and 3 h after injection of 68Ga-
MMC(IR800)-TOC. (a) Coronal images and maximum-intensity projections (MIPs) are shown 
(arrow indicates tumor). (b) Ratio of the signal in tumor and background tissue. Data are 
presented as mean ± standard deviation (n=3).  
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Determination of optimal imaging time point  
We previously observed that 68Ga-MMC(IR800)-TOC undergoes time-dependent 
clearance from circulation and tissues up to 3 h post-injection. Therefore, we selected the 3 h 
time point for the initial in vivo NIRF imaging experiments. The in vivo kinetics of non-radioactive 
Ga-MMC(IR800)-TOC were qualitatively and semi-qualitatively evaluated in mice bearing 
subcutaneous HCT116-SSTR2 xenografts using a custom-built EMCCD fluorescence imaging 
system.  
Early optical imaging showed inconsistent tumor delineation, alongside prominent kidney 
signal and background fluorescence in the thoracic and abdominal walls (Fig. 12a). We 
hypothesized that this inconsistency was a result of low agent accumulation, slow elimination 
from background tissues or a combination of the two. Thus, NIRF imaging was repeated 24 h 
post-injection (Fig. 12a). Delayed imaging showed clear tumor delineation and contrast 
enhancement. Semi-qualitative analysis of the normalized fluorescent signal indicates that the 
contrast gain in the tumor is a combination of signal retention and a 2-fold signal reduction from 
background regions (Fig. 12b). 
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Figure 12. In vivo NIRF imaging of Ga-MMC(IR800)-TOC in mice. (a) Representative NIRF 
images of Ga-MMC(IR800)-TOC were acquired in HCT116-SSTR2 xenografts at early and delayed 
time points using a custom EMCCD fluorescence imaging system. Solid arrows indicate tumor, 
dashed arrows indicate kidney. (b) Normalized fluorescence signal in tumor and background 
tissue. * P< 0.005. Data are presented as mean ± standard deviation (n=5). 
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Ex vivo quantitative analysis and nuclear/NIRF contrast determination 
 A major advantage for dual labeling an FGS agent is the inherent ability to quantify its 
biodistribution for cross-validation of the optical data. Accordingly, the radioactive utility of the 
MMC was used to produce dual labeled conjugates for early (3 h, 68Ga) and delayed (24 h, 67Ga) 
biodistribution studies. Ex vivo evaluation by IVIS imaging of resected organs was in agreement 
with in vivo results (Fig. 13a). Agent uptake in the tumor was similar at 3 and 24 h and clearance 
was primarily through the kidneys. Moderate liver signal was observed at both time points, but 
the early lung fluorescence was reduced to background levels at 24 h indicating washout from 
non-target sites. Fluorescence was minimal at both time points in other healthy tissues and 
importantly in sites that endogenously express low/intermediate SSTR2 levels (small intestine, 
pancreas, and stomach) (111). 
Analysis of fluorescence intensity is summarized in Figure 13b and Table 4, with 
corresponding optical contrast ratios shown in Figure 13c. Accumulation of the fluorescent signal 
in the tumor was rapid and sustained with no significant change up to 24 h, and was higher than 
non-clearance organs. Clearance was primarily through the kidneys, which showed constant 
signal over time. The NIRF signal decreased significantly at 24 h for most of the remaining tissues 
and remarkably in the small intestine (22.8%, P < 0.01), muscle (29%, P < 0.05) and lung (51.3%, 
P < 0.01). The reduction of the NIRF signal translated into 1.3 and 1.8-fold contrast 
enhancements in tumor-to-muscle (P < 0.05) and tumor-to-lung (P < 0.05) ratios, respectively. 
Importantly, the pancreas and small intestine had constant contrast ratios of >2.5, while for the 
lungs, the ratio increased from 1.40±0.40 to 2.52±0.27, which is critical since a TBR of at least 2 
is generally accepted as being suitable for tumor delineation in the operating room. 
Radioactive biodistribution results are summarized in Figure 13d and Table 5, with 
corresponding tumor-to-tissue ratios shown in Figure 13e.  At 3 h, administration of 68Ga-
MMC(IR800)-TOC resulted in high renal clearance (45.6±3.8 %ID/g), along with prominent 
accumulation in the lungs (6.7±0.9 %ID/g), liver (5.0±0.9 %ID/g), and stomach (4.5±0.8 %ID/g). 
Tracer accumulation of 3.54±0.85 %ID/g was measured in the tumor and was higher than 
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pancreas (1.7±0.2 %ID/g) and small intestine (1.3±0.1 %ID/g). Analysis of the 24 h biodistribution 
data showed similar tumor uptake of 67Ga-MMC(IR800)-TOC compared to the 3 h group 
(4.26±1.08 %ID/g, P > 0.05). Importantly, reduction in signal was seen in most tissues that were 
not involved in clearance. Most notably, tracer signal decreased by 64.6% in muscle (P < 0.01) 
and 84.3% in blood (P < 0.001), yielding tumor-to-muscle and tumor-to-blood values of 18.9±3.7 
and 11.5±3.4, respectively, and a 3.1-fold (muscle) and 7.1-fold (blood) increase from values 
obtained at 3 h. In tissues relevant to NET surgeries, tumor-to-tissue ratios improved significantly 
for the lung (P < 0.01) to a final value of 1.50±0.43 (2.8-fold increase). 
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Figure 13. Quantitative biodistribution assessment by dual labeling. (a) Ex vivo optical images 
(IVIS) of organs resected from HCT116-SSTR2 xenografts that were injected with 
68
Ga-
MMC(IR800)-TOC or 
67
Ga-MMC(IR800)-TOC. Determination of (b) tissue fluorescence by 
analysis of IVIS imaging and (c) corresponding contrast ratios at major sites of NET incidence 
(pancreas, small intestine, lung) and selected non-target sites (muscle and blood). 
Determination of (d) radioactive uptake by gamma counting and (e) corresponding gamma 
counting ratios. * P< 0.05, ** P< 0.01, ***P< 0.001. Data are presented as mean ± standard 
deviation (n=5). Average radiant efficiency displayed as ([p/s/cm²/sr]/[µW/cm²]). S.I., small 
intestine.  
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 68Ga-MMC(IR800)-TOC 67Ga-MMC(IR800)-TOC 
 3 h   24 h  
Tumor 231,420 ± 60,115   205,075  ± 22,691  
Muscle 50,478 ± 9,203   35,825 ± 1,259  
Pancreas 90,390 ± 9,067   79,425 ± 13,594  
S. Intestine 54,856 ± 4,742   42,345 ± 1,934  
Lung 169,480 ± 38,156   82,583 ± 15,944  
Liver 139,440 ± 17,199   162,650 ± 8,012  
Spleen 58,998 ± 9,312   40,875 ± 1,963  
Stomach 84,198 ± 11,288   60,978 ± 10,560  
Kidney 1,152,800 ± 129,635   1,456,500 ± 302,673  
Bone 87,696 ± 9,263   61,505 ± 7,635  
Heart 60,228 ± 4,068   45,813 ± 12,630  
Adrenal 93,834 ± 20,315   86,138 ± 42,056  
Table 4. Average radiant efficiency × 10
3
 ([p/s/cm²/sr]/[µW/cm²]) results for 
68
Ga-
MMC(IR800)-TOC and 
67
Ga-MMC(IR800)-TOC. 
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68Ga-MMC(IR800)-TOC 67Ga-MMC(IR800)-TOC 
 
3 h 
  
24 h 
  
Tumor 3.54 ± 0.85 
  
4.26 ± 1.08 
  
Muscle 0.64 ± 0.12 
  
0.22 ± 0.05 
  
Pancreas 1.67 ± 0.21 
  
1.44 ± 0.13 
  
S. Intestine 1.29 ± 0.13 
  
1.05 ± 0.21 
  
Lung 6.68 ± 0.89 
  
2.90 ± 0.83 
  
Liver 5.04 ± 0.88 
  
5.03 ± 0.54 
  
Spleen 3.16 ± 0.94 
  
1.64 ± 0.46 
  
Stomach 4.48 ± 0.77 
  
2.85 ± 0.16 
  
Brain 0.12 ± 0.06 
  
0.03 ± 0.00 
  
Blood 2.38 ± 0.23 
  
0.37 ± 0.05 
  
Kidney 45.58 ± 3.77 
  
36.81 ± 2.64 
  
Bone 1.80 ± 0.43 
  
0.85 ± 0.04 
  
Heart 2.12 ±0.82 
  
0.55 ± 0.03 
  
Adrenal 2.30 ± 2.85 
  
1.11 ± 0.16 
  
Urine 56.13 ± 18.23 
  
5.14 ± 0.98 
  
Table 5. Biodistribution results (%ID/g) for 
68
Ga-MMC(IR800)-TOC and 
67
Ga-MMC(IR800)-TOC. 
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Specificity for SSTR2 imaging in vivo 
SSTR2-mediated-targeting of our optical probe was evaluated by using 1) mice with 
HCT116-SSTR2 and HCT116-WT tumors, and 2) the non-targeted MMC analog, Ga-
MMC(IR800), in HCT116-SSTR2 mice. In vivo imaging showed clear Ga-MMC(IR800)-TOC 
signal in HCT116-SSTR2 tumors but not in WT tumors lacking SSTR2 expression (Fig. 14a). Ex 
vivo IVIS imaging was in agreement with in vivo results (Fig. 14b) and subsequent image analysis 
showed a higher (P < 0.01) average radiant efficiency emitted from the HCT116-SSTR2 
xenograft compared to the WT tumors and non-targeted analog (Fig. 14c). This, in turn, resulted 
in TBRs that were 1.8, 1,8, 2.3, and 2.4-fold higher than WT in the muscle, pancreas, small 
intestine, and lung of HCT116-SSTR2 mice, respectively (Fig. 14d). 
Mesoscopic analysis of frozen sections confirmed the in vivo and ex vivo imaging results 
and showed specific, localized Ga-MMC(IR800)-TOC uptake only in HCT116-SSTR2 tumors 
(Fig. 15a). H&E staining showed that agent uptake was confined to viable areas of the HCT116-
SSTR2 tumor, while no accumulation was observed in the WT counterpart (Fig. 15a). The signal 
in HCT116-SSTR2 tumors was 8.6-fold higher than in SSTR2-deficient tumors, while the signal 
in pancreas, muscle and small intestine are comparably low between the groups (Fig. 15b). On 
the microscopic level, we observed an intracellular agent accumulation in HCT116-SSTR2 
tumors, while we did not detect the NIRF signal in HCT116-WT tumors (Fig. 15c). 
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Figure 14. In vivo and ex vivo specificity of Ga-MMC(IR800)-TOC. (a) In vivo NIRF imaging in 
HCT116-SSTR2 and HCT116-WT subcutaneous xenografts acquired 24 h post-injection of Ga-
MMC(IR800)-TOC with a custom-built EMCCD fluorescence imaging system. The non-targeted 
Ga-MMC(IR800) in HCT116-SSTR2 mice was similarly evaluated. Arrows indicate tumor. (b) Ex 
vivo NIRF imaging of selected organs using an IVIS Lumina II. (c) Tissue fluorescence determined 
from analysis of IVIS imaging. (d) Optical contrast provided by the ratio of the average 
fluorescent signal in the tumor to sites of NET formation. * P< 0.05, ** P< 0.01, ***P< 0.001. 
Data are presented as mean ± standard deviation (n=5). Average radiant efficiency displayed as 
([p/s/cm²/sr]/[µW/cm²]). 
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Figure 15. Multiscale imaging of Ga-MMC(IR800)-TOC uptake.  (a) Confirmation of in vivo 
accumulation of Ga-MMC(IR800)-TOC in HCT116-SSTR2 and HCT116-WT xenografts and organs 
via frozen section imaging using the Odyssey NIR scanner. H&E sections provide morphological 
reference. (b) Quantification of the fluorescence signal of tumor and organ frozen section 
Odyssey scans (Means and standard deviations of n=3 animals/group). (c) Microscopic 
detection of in vivo injected Ga-MMC(IR800)-TOC. Frozen sections from resected HCT116-
SSTR2 and HCT116-WT tumors were counterstained with a nuclear stain (Nucspot488), fixed 
and examined under a confocal microscope. An NIR signal was only detected in HCT116-SSTR2 
tumor, corresponding to the SSTR2 expression in this model, while it was absent in SSTR2 
negative HCT116-WT tumors. Experiments were performed by Dr. Susanne Kossatz and Dr. 
Thomas Reiner in the Department of Radiology, Memorial Sloan Kettering Cancer Center, New 
York. 
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Effect of injected dose on image contrast 
The detection of small lesions while maintaining a high tumor-to-background ratio is a 
major challenge for FGS. The answer to the question of “what is the smallest amount of cancer 
that this technique can detect?” is a function of the sensitivity and specificity of both the optical 
agent and the imaging device (41). Thus, we evaluated the interplay between injected amount 
and contrast by comparing the effects of low (0.5 nmol) and high (2 nmol) dose administration of 
Ga-MMC(IR800)-TOC in SSTR2-expressing tumors at 24 h. Ex vivo IVIS imaging showed higher 
tumor fluorescence with the 2 nmol group. However, the higher dose also resulted in the amplified 
non-specific accumulation of signal in non-target and healthy tissues (Fig. 16a). Image analysis 
confirmed that although a larger dose yields a 3.8-fold increase (P < 0.001) in total fluorescent 
output in the tumor, it also elevates fluorescence in non-tumor tissues and raises the background 
signal by >6-fold in the pancreas, small intestine and lung (P < 0.001) (Fig. 16b). The increase 
in NIRF signal at 2 nmol/mouse resulted in an approximately 40% reduction in tissue contrast 
compared to 0.5 nmol/mouse (Fig. 16c). Since an elevated noise floor could offset the high signal 
in the tumor and impair intraoperative visualization of NETs, we identified 0.5 nmol as the starting 
point for future in vivo studies. 
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Figure 16. Effect of injection mass on optical contrast. (a) Macroscopic NIRF imaging of 
resected organs following administration of 0.5 nmol and 2 nmol. (b) Tissue fluorescence 
measured by IVIS imaging following injection of Ga-MMC(IR800)-TOC at 0.5 nmol and 2 nmol 
per mouse. (c) Optical contrast provided by the ratio of the average fluorescent signal in the 
tumor to sites of tumor formation. * P< 0.05, ** P< 0.01, ***P< 0.001. Data are presented as 
mean ± standard deviation (n=5). Average radiant efficiency displayed as 
([p/s/cm²/sr]/[µW/cm²]). 
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CHAPTER 4: DISCUSSION 
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The gap between pre- and intraoperative imaging emphasizes the tremendous difficulties 
of navigating the translational pathway and the need for new methods to validate FGS agents. 
In an effort to overcome these difficulties, we hypothesize that the clinical radiotracer 68Ga-DOTA-
TOC would serve as an ideal system for developing a fluorescent analog for the specific targeting 
of SSTR2 for FGS in NETs. With the implementation of the innovative MMC linker, which 
functions as a spacer and radioactive core to bridge TOC and IR800, we were able to generate 
a fluorescent DOTA-TOC analog with minimal structural deviations. The application of the dual 
labeling strategy permits cross-validation through “true” quantification and NIRF/nuclear signal 
co-localization, while having 68Ga-DOTA-TOC as a clinical benchmark facilitates pre-clinical 
evaluation. Importantly, our approach complements SSTR2-targeted radiotracers (i.e., 68Ga-
DOTA-TOC and 68Ga-DOTA-TATE). The pre-operative PET with a gold standard will accurately 
identify the number of lesions and will be combined with CT/MRI to establish a surgical plan. The 
surgeon can then navigate per standard of care to the appropriate location and utilize the contrast 
provided by Ga-MMC(IR800)-TOC to remove lesions. 
Numerous methods are available for 68Ga-DOTA-TOC radiosynthesis. For testing 68Ga-
MMC(IR800)-TOC labeling, we selected the fractionation, acetone and NaCl methods as 
formulations with translational relevance. Each one of these methods has advantages and 
disadvantages that define their suitability for specific applications. Fractionation is a well-
established radiochemical method where 68Ga is eluted from the 68Ge/68Ga-generator in fractions 
and the portion with the highest activity (~80% of activity concentrated in 1 mL of eluate) is 
selected for direct incubation with the tracer (112). Concerns with 68Ge and metal (i.e., Zn(II)) 
breakthrough drove the development of alternate radiosynthetic procedures that include pre-
concentration and purification of the initial 68Ga eluate using exchange chromatography. 
Zhernosekov et al. reported the now widely adopted successful purification of the 68Ga eluate 
using a cation-exchanger with acetone recovery for high radiochemical yield (113). Recently, 
Mueller et al. has substituted the use of the organic solvent acetone (desirable for medical 
applications), with a NaCl-based solution for the production of radioconjugates with high specific 
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activities (114). Here, using these clinical radiochemistry formulations, we found that the MMC 
complex coordinates 68Ga, 67Ga and Ga with high radiochemical yield and stability in serum, 
which suggests that the MMC is a suitable DOTA substitute for in vivo applications and a versatile 
chelator for metals and radiometals. As we move forward with testing new dyes and targeting-
peptides, this radiochemical flexibility would permit the customization and optimization of 
radiolabeling conditions. 
In a dual labeled format, the performance of the fluorescent dye critically depends on the 
preservation of the stability and optical properties upon subjection to radiolabeling. Labeling 
formulations require a wide range of buffers, eluting solutions, pH ranges, heating temperatures, 
etc. These differing factors coupled to varying concentrations of radioactivity may impact the 
spectral properties of the dye. In a previous study by our group (51), it was shown that the relative 
brightness (RB) of IR800 remains relatively unchanged at room temperature in the presence of 
Ga and in NaOAc solutions ranging from 0.1-1.25 M and pH 4-6. In a follow up experiment, IR800 
was added to 1.25 M NaOAc (pH 4) and heated to 95° C for 10 min with varying levels of 68Ga 
activity to simulate in vitro (0.6 mCi, low), in vivo (1.6 mCi, medium) and human studies (4.1 mCi, 
high). Results showed that while the RB remained >2 and similar to that of the non-radioactive 
buffer system for the low and medium activity doses, the radioactive solution with the highest 
dose caused the RB to drop below 2. Similarly, in the present study we evaluated whether the 
selection of radiolabeling scheme resulted in differences in fluorescence intensity. The 
fractionation and acetone formulations yielded the highest signal retention and results were in 
agreement with previous work by our group. The acetone formulation was selected for 
subsequent in vivo applications based on high fluorescence retention and the ability to purify/pre-
concentrate 68Ga for production of 68Ga-MMC(IR800)-TOC with high specific activity. 
Retention of pharmacological properties is another crucial pre-clinical endpoint when 
developing a targeted agent that combines NIRF and nuclear contrasts. Agonist-induced 
mechanisms have been a paradigm used by radiolabeled SSAs for nuclear imaging and PRRT. 
This paradigm is established on the putative ability of somatostatin agonists to inhibit cAMP 
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production and to induce the internalization of the ligand-receptor complex (77, 78). Previously, 
dual labeled SSAs have been reported to lose the ability to bind the receptor (101) and internalize 
(102) upon dye attachment. Thus, we investigated the impact of fluorescent functionalization on 
these fundamental radiotracer characteristics. We examined receptor kinetics with 
pharmacological assays and radioactive uptake studies, which indicated that 68Ga-MMC(IR800)-
TOC maintains intact binding and molecular mechanisms of action at comparable 68Ga-DOTA-
TOC potencies. These in vitro pharmacodynamic results have been confirmed by analysis of the 
subcellular localization of the agent using confocal microscopy (100). 
Image contrast is dependent on agent accumulation in tumors and clearance from 
background tissues. In healthy mice, we found that 68Ga-MMC(IR800)-TOC underwent time-
dependent elimination from circulation and background tissues up to 3 h post-injection. Since 
similar findings were shown by PET/CT imaging in SSTR2-overexpressing xenografts, we 
selected 3 h as the initial time point for in vivo NIRF imaging but found that tumors were not 
clearly visualized. Given the continuous washout of agent from normal tissues, we extended the 
imaging study to 24 h to enable further clearance and showed clear delineation of tumors in all 
mice. Since optical imaging is not quantitative, we produced radioactive analogs for early (68Ga) 
and delayed (67Ga) biodistribution studies to further evaluate tissue uptake. From those 
experiments, we confirmed that clearance from background organs was the major factor 
contributing to the improved focal signal being detected from the cancer lesion at 24 h. 
Importantly, tissue uptake and contrast ratios obtained by gamma counting were essentially 
identical to the ex vivo optical data and demonstrated the intrinsic utility of dual labeling as a tool 
for validating an FGS agent. 
The efficacy of an FGS agent has been defined by FDA guidance documents as the ability 
to distinguish between normal and abnormal anatomy (42). Attempting to detect microscopic 
disease in a macroscopic setting, namely the surgical field of view, further compounds the 
difficulties of using an FGS agent effectively. Surgical resection of primary NETs is most 
commonly performed in the pancreas, small intestine, or lungs. Therefore, low accumulation of 
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Ga-MMC(IR800)-TOC in these tissues is necessary in order to generate suitable contrast for 
determining surgical margins or lymph node metastases. Macroscopic ex vivo imaging showed 
that our agent can provide contrasts of >2 in pancreas and lungs, and >4.5 in muscle and small 
intestine. Importantly, these TBRs were acquired without dose optimization or an accompanying 
imaging device. Suitable contrast ratios for FGS are difficult to define given the increasing 
number of drug-device combinations in the OR. However, our results compare favorably to pre-
clinical and clinical TBRs during fluorescence-guided resection of tumors (34, 39, 115) and 
indicate potential for intraoperative visualization of NET deposits using Ga-MMC(IR800)-TOC. 
 Previous work by our group showed SSTR2-mediated uptake of a 64Cu labeled 
MMC(IR800)-TOC analog using in vitro and in vivo studies, where competition with octreotide 
strongly reduced uptake in SSTR2 expressing tumors (57). In addition, a probe variant with a 
scrambled peptide showed very low tumor uptake. The present study further confirms the intact 
in vivo receptor specificity provided by TOC as shown by clear differences in tumor fluorescence 
between HCT116-SSTR2 and HCT116-WT tumors macroscopically (in vivo, ex vivo) and 
microscopically. Additionally, a non-targeted analog showed decreased tumor uptake. 
 Identifying the optimal injection dose can also attain improved image contrast. In the case 
of radiotracers, both labeled (i.e., 68Ga-DOTA-TOC) and unlabeled (i.e., DOTA-TOC) species 
are present upon administration and could result in competition for binding sites and reduce 
radioactive signal in tumors. Fluorescent agents generally consist of a single chemical species 
and do not experience such effects. Therefore, optical probes may not necessarily need to 
adhere to microdoses and may benefit from increased agent dosage. Rosenthal et al. previously 
showed that following the administration of 2.5, 25 and 62.5 mg cetuximab-IR800/m2, the TBRs 
of resected human tumors using closed-field imaging were highest with the middle dose (34).  
Since larger doses may also produce more non-targeted uptake that reduces contrast 
and negatively affects specificity, we examined the correlation between injected dose and 
absolute fluorescence by injecting xenografts with 0.5 or 2 nmol of Ga-MMC(IR800)-TOC. 
Although the 2 nmol dose produced a nearly 4-fold increase in tumor fluorescence, TBRs were 
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all higher with the low-dose cohort. This is likely attributable to non-specific binding of Ga-
MMC(IR800)-TOC that is amplified at higher doses and suggests more effective tumor 
visualization at lower injection amounts. Further dose optimization studies could identify maximal 
TBRs that reduce the potential of false-positives and enhance predictive value and diagnostic 
accuracy. 
Recently, there has been a surge of interest in evaluating tumor margins with surgical 
specimen mapping. This strategy consists in utilizing closed-field devices with a controlled 
environment for back-table fluorescence imaging of surgical resections. This method has been 
proposed as a complementary tool during in situ surgical navigation for screening intraoperative 
margin samples and prioritizing the fluorescent ones for further examination. Clinical studies 
have effectively integrated ex vivo macroscopic imaging as a validation method with implications 
for fluorescence-guided pathology. In one study, the accumulation of panitumumab-IR800 in 
surgical samples highly correlated with tumor location with sensitivities and specificities >89%, 
while the NIRF signal predicted the distance of tumor tissue to the cut surface of the specimen 
(115). In another study with bevacizumab-IR800, an analytical framework for correlating 
intraoperative fluorescence signals with histopathology was applied and demonstrated an 88% 
increase in detection rates of tumor-involved margins (116). In order to examine tissue mapping 
with Ga-MMC(IR800)-TOC, we correlated SSTR2 expression via IHC with H&E staining and 
NIRF signal accumulation in frozen sections prepared from mouse xenografts. While H&E 
provides boundary demarcation of tumor from non-tumor tissue, IHC identifies and determines 
the distribution of SSTR2 expression. Thus, this histopathological combination serves as a 
method for assessing the binding and delineation specificity of Ga-MMC(IR800)-TOC. Frozen 
section analysis of HCT116-SSTR2 xenografts treated with Ga-MMC(IR800)-TOC revealed 
fluorescent delineation of tumor from non-tumor tissue in excellent agreement with tumor 
morphology and expression status determined by H&E and IHC staining, respectively. 
Conversely, negligible signal was produced from the SSTR2-defficient tumor and healthy tissues. 
These results showed the potential clinical effectiveness of Ga-MMC(IR800)-TOC for specifically 
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delineating tissues based on the presence of SSTR2 and indicate promising potential for image-
guided NET pathology. 
 In summary, we demonstrated for the first time that an SSTR2-targeted FGS agent can 
be used for highly specific tumor targeting. Importantly, we showed an excellent strategy for the 
intact retention of agonist-induced mechanisms and in vitro/in vivo receptor-targeting capabilities 
upon dye conjugation to the most commonly used SSA for PET imaging in NETs. Our results 
also showed the effectiveness of the MMC technology for combining fluorescent and nuclear 
contrast into a single targeted probe. We presented the advantages of applying the radioactive 
utility of the MMC for cross-validating and quantifying the pharmacokinetics of the resulting FGS 
agent. Finally, imaging at the macro, meso and microscopic scales provided comprehensive 
validation of receptor-mediated uptake and strongly indicate translational utility for FGS in NETs.  
 
Future Directions 
 There are two major areas that we are actively looking to investigate further. The first one 
involves the determination of a strategy for significantly reducing the prominent liver signal that 
we have observed up to 24 h. A decrease in liver signal could potentially allow the delineation of 
SSTR2 overexpressing lesions in the hepatic system. This interest arises from the well-
established role of neuroendocrine liver metastases that largely contribute to mortality rates in 
NET patients. To put it into context, more than 40% of NET patients develop metastatic liver 
burden over the course of the disease and have a 5-year survival rate ranging from 13 to 54% 
(69). Our initial assessment will focus on further optimizing the injected dose and extending the 
time for imaging relative to agent administration. The results of this study will provide insight to 
the question “how low can we go and still acquire relevant TBRs?” at sites of NET formation. 
Additionally, we will determine whether Ga-MMC(IR800)-TOC either requires more time for 
clearance from the liver (i.e., signal at 24 h vs. 48 h) or whether dye conjugation causes 
irreversible liver retention. Subsequently, we are interested in substituting the highly anionic 
IR800 for a NIRF dye with comparable optical properties, but with reduced anionic burden and a 
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well-balanced charge distribution over its surface (i.e., ZW800-1). We hypothesize that this 
switch could improve the pharmacokinetic disposition of our FGS agent by means of faster 
elimination from non-target tissues, while also reducing non-specific signal accumulation. 
 The second area that we are looking to further investigate is the sensitivity and specificity 
of our FGS agent using a metastatic animal model. Clinically, SSTR2 overexpressing 
malignancies will continue to be diagnosed using a gold standard. Importantly, patients that have 
been identified as candidates for surgery using 68Ga-DOTA-TOC or -TATE, would be candidates 
for FGS with Ga-MMC(IR800)-TOC. Thus, it is critical to evaluate the ability of our FGS agent to 
target tumor deposits that have been previously identified using PET/CT with 68Ga-DOTA-TOC. 
The results of this study will complement our strong in vivo specificity data and provide the 
groundwork prior to transitioning to imaging larger animals (i.e., pigs) with 68Ga-DOTA-TOC and 
Ga-MMC(IR800)-TOC. 
 Altogether, these findings will also serve as the basis and benchmark as we transition 
towards the application of Ga-MMC(IR800)-TOC in other disease models with SSTR2 
overexpression. Several tumors of the nervous system have been shown to express SSTR2 at 
high density (77). Specifically, studies have shown that SSTRs are overexpressed in more than 
90% of neuroblastoma (117) and medulloblastoma (118) tumors in children, while clinical studies 
continue to investigate their implication for diagnosis and therapy (119). Recently, Dijkstra et al. 
reported the establishment of SSTR2 as the “most promising receptor for meningioma targeting” 
(120) with excellent potential for intraoperative imaging using targeted contrast agents. Thus, 
candidates for surgery within this patient population could benefit from FGS with Ga-
MMC(IR800)-TOC. 
 Finally, given versatility of the MMC technology, we are interested in expanding the role 
of our radioactive linker for the assessment of not only targeting approaches beyond TOC (i.e., 
other peptides, small molecules), but for also evaluating other therapeutic strategies. The 
conjugation of a reporter or payload to the MMC occurs through copper-free click chemistry – an 
ever-growing field that facilitates the development of targeted probes through incorporation of 
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reactive groups for facile bioconjugation. Therefore, the practicality of a “plug-and-play” platform 
via the MMC provides an efficient method for the rapid synthesis and investigation of systemic 
therapies including peptide-drug conjugates (i.e., with MMAE) and photodynamic therapy (i.e., 
with IR700DX). These theranostic agents could be a valuable alternative for patients with 
advanced stages of SSTR2-positive metastases, where surgery may not be an option. 
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